Sutro Biopharma Presents Data from Dose-Optimization Portion of REFR?ME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.